Add BrightSurf on Google Email

University of Kentucky


Cancer-resistant mouse discovered

A team of researchers has discovered a tumor-suppressor gene called Par-4 that kills cancer cells but not normal cells. The mice born with this gene live longer and have no toxic side effects, making it a potentially therapeutic application for treating cancer without harming patients.

SourceUniversity of Kentucky·JournalCancer Research·DateNov 27, 2007

Does OTC diet pill Alli live up to its name?

A study by the University of Kentucky found that OTC strength orlistat (Alli) resulted in significant weight loss, with participants losing approximately 7-15 pounds over four months. The study also demonstrated a reduction in LDL-cholesterol and associated heart health benefits.

SourceUniversity of Kentucky·JournalAnnals of Pharmacotherapy·DateJun 13, 2007

UK researchers find new class of nontoxic cancer treatments

UK pharmaceutical sciences graduate student Abby Ho and assistant professors Kyung-Bo Kim and Royce Mohan developed a new compound dubbed UK-101 that acts directly on LMP2, a component of the immune proteasome variant abundantly expressed in certain tumors. The researchers found that UK-101 inhibits LMP2 while not attacking normal cell...

SourceUniversity of Kentucky·JournalChemistry & Biology·DateMay 1, 2007

Heart intervention doesn't outweigh medicine in study

A new five-year study published in the New England Journal of Medicine found that stable heart patients received no significant benefit from undergoing angioplasty compared to those treated with medication alone. The study showed a 19.5% rate of death, heart attack, and stroke among medication-only patients versus 20% for PCI recipients.

SourceUniversity of Kentucky·JournalNew England Journal of Medicine·DateMar 27, 2007

New blood thinner may work without bleeding risk

A new thrombin-receptor antagonist (TRA) has shown significant reduction in serious cardiovascular events, mainly heart attacks, with no increase in bleeding risks in a high-risk patient population. The study found a 46% lowering in serious cardiovascular events, an early and strong efficacy signal for this novel antiplatelet compound.

Intrinsic eye protein halts angiogenesis

Scientists identified SFLT-1 as the protein responsible for preventing blood vessel growth in corneas. Deactivating this protein allows angiogenesis to occur, leading to conditions such as macular degeneration and cancer. The discovery opens doors to new treatments by harnessing the natural anti-angiogenic properties of the eye.

SourceUniversity of Kentucky·JournalNature·DateOct 18, 2006

Safer suntans through science

Scientists at the University of Kentucky are testing a lotion that stimulates melanin production, reducing UV damage and increasing skin protection. The treatment has promising results, offering an alternative to traditional sunless tanning products and tanning beds.

SourceUniversity of Kentucky·JournalNature·DateSep 26, 2006

Researchers develop blood test to detect lung cancer

Researchers at the University of Kentucky have developed a blood test to detect lung cancer in early stages, showing 90% accuracy in predicting non-small-cell lung cancer. The test identifies the body's immune response to tumors and could become the first blood test to predict cancer since the PSA test was introduced.

SourceUniversity of Kentucky·JournalJournal of Thoracic Oncology·DateJul 31, 2006

New benefits of soy revealed

Researchers found that soy-based meal replacements led to greater weight loss and improved cholesterol levels compared to milk-based alternatives. Additionally, soy intake was shown to reduce serum glucose values, suggesting a role in maintaining overall health and slowing diabetes development.

SourceUniversity of Kentucky·JournalJournal of the American College of Nutrition·DateJun 7, 2005